XML 73 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions (Tables)
12 Months Ended
Dec. 31, 2012
Total Consideration Transferred

The total consideration transferred follows:

 

Cash consideration

   $ 26,445,000   

Estimated fair value of contingent consideration

     1,611,000   
  

 

 

 

Total consideration transferred

   $ 28,056,000   
  

 

 

 
Novozymes Biopharma Sweden Ab
 
Summary of Allocation of Consideration Transferred

The following chart summarizes the allocation of the fair value of assets acquired and liabilities assumed:

 

Accounts receivable

   $ 5,088,000   

Inventory

     10,497,000   

Prepaid expenses

     180,000   

Fixed assets

     9,089,000   

Customer relationships and acquired technology

     6,705,000   

Deferred tax liability

     (198,000

Accounts payable and other liabilities assumed

     (2,563,000
  

 

 

 

Net assets acquired

   $ 28,798,000   

Less total consideration transferred

     (28,056,000
  

 

 

 

Gain on bargain purchase

   $ 742,000   
  

 

 

 
Bio Flash Partners Limited Liability Company
 
Summary of Allocation of Consideration Transferred

The following chart summarizes the allocation of consideration transferred:

 

Intangible assets subject to amortization

   $ 1,430,000   

Goodwill

     994,000   

Equipment

     216,000   
  

 

 

 

Total

   $ 2,640,000